Stock LTRN LANTERN PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Market Closed - Nasdaq
Other stock markets
 01:30:00 02/07/2024 am IST 		5-day change 1st Jan Change
4.52 USD -3.21% Intraday chart for Lantern Pharma Inc. +15.60% +5.61%
12/06 Lantern Pharma Secures Composition of Matter Patent for LP-284 in Japan MT
12/06 Lantern Pharma Inc. Receives Certificate of Patent from Japanese Patent Office for Composition of Matter Covering Drug Candidate LP-284 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office for Composition of Matter Covering Drug Candidate LP-284
AQ
Lantern Pharma Secures Composition of Matter Patent for LP-284 in Japan
MT
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
BU
Lantern Pharma Inc. Receives Certificate of Patent from Japanese Patent Office for Composition of Matter Covering Drug Candidate LP-284
CI
Lantern Pharma : Corporate Overview
PU
Transcript : Lantern Pharma Inc. - Special Call
Lantern Pharma Files $150 Million Mixed Shelf
MT
Lantern Pharma : Corporate Overview
PU
Transcript : Lantern Pharma Inc., Q1 2024 Earnings Call, May 09, 2024
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
BU
Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration
MT
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
BU
Lantern Pharma Inc. Announces A Strategic AI-Driven Collaboration with Oregon Therapeutics to Optimize the Development of its First-In-Class Protein Disulfide Isomerase Inhibitor Drug Candidate XCE853 in Novel and Targeted Cancer Indications
CI
Lantern Pharma to Report First Quarter 2024 Operating and Financial Results on May 9th, 2024 at 4:30 p.m. ET
AQ
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
BU
Lantern Pharma Launches Webinar Wednesdays Featuring World-Class Physician Scientists and Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
AQ
Transcript : Lantern Pharma Inc. - Special Call
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
BU
Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LTRN Stock
  4. News Lantern Pharma Inc.